drugset / Trial / NCT05995041
Universal CAR-T Cells Targeting AML
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML. The study also aims to learn more about the function of the universal CAR T cells and their persistency in AML patients.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells | Cell therapy | — | Other |